Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORIENT-99 perioperative sintilimab plus chemotherapy in resectable NSCLC
CTR20212822Phase 3Active
- Sponsor
- InnoCare Pharma
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by InnoCare Pharma. Started Mar 2024; status: active.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20212822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212822.